Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study — Rutao Wang (2021) | RDL Network
Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study
Clinical Research in Cardiology 110(10): 1543-1553
Article 2021 English
Authors
RW
Rutao Wang
KT
Kuniaki Takahashi
SG
Scot Garg
Abstract
1 min read
Background Coronary bypass artery grafting (CABG) has a higher procedural risk of stroke than percutaneous coronary intervention (PCI), but may offer better long-term survival. The optimal revascularization strategy for patients with prior cerebrovascular disease (CEVD) remains unclear. Methods and results The SYNTAXES study assessed the vital status out to 10 year of patients with three-vessel disease and/or left main coronary artery disease enrolled in the SYNTAX trial. The relative efficacy of PCI vs. CABG in terms of 10 year all-cause death was assessed according to prior CEVD. The primary endpoint was 10 year all-cause death. The status of prior CEVD was available in 1791 (99.5%) patients, of whom 253 patients had prior CEVD. Patients with prior CEVD were older and had more comorbidities (medically treated diabetes, insulin-dependent diabetes, metabolic syndrome, peripheral vascular disease, chronic obstructive pulmonary disease, impaired renal function, and congestive heart failure), compared with those without prior CEVD. Prior CEVD was an independent predictor of 10 year all-cause death (adjusted HR: 1.35; 95% CI: 1.04–1.73; p = 0.021). Patients with prior CEVD had a significantly higher risk of 10 year all-cause death (41.1 vs. 24.1%; HR: 1.92; 95% CI: 1.54–2.40; p < 0.001). The risk of 10 year all-cause death was similar between patients receiving PCI or CABG irrespective of the presence of prior CEVD (p -interaction = 0.624). Conclusion Prior CEVD was associated with a significantly increased risk of 10 year all-cause death which was similar in patients treated with PCI or CABG. These results do not support preferential referral for PCI rather than CABG in patients with prior CEVD. Trial registration: SYNTAX: ClinicalTrials.gov reference: NCT00114972 . SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050. Graphic abstract
Rutao Wang, Patrick W. Serruys, Chao Gao, Hironori Hara, Kuniaki Takahashi, Masafumi Ono, Hideyuki Kawashima, Neil O’Leary, David R. Holmes, Adam Witkowski, Nick Curzen, Francesco Burzotta, Stefan James, Robert‐Jan van Geuns, A. Pieter Kappetein, Marie‐Angèle Morel, Stuart J. Head, Daniel J.F.M. Thuijs, Piroze Davierwala, Timothy O’Brien, Valentı́n Fuster, Scot Garg, Yoshinobu Onuma
Kuniaki Takahashi, Daniel J.F.M. Thuijs, Chao Gao, Masafumi Ono, David R. Holmes, Michael J. Mack, Marie‐Claude Morice, Friedrich‐Wilhelm Mohr, Nick Curzen, Piroze Davierwala, Milan Milojevic, Keith D. Dawkins, Joanna J. Wykrzykowska, Robbert J. de Winter, John W. McEvoy, Yoshinobu Onuma, Stuart J. Head, A. Pieter Kappetein, Patrick W. Serruys
Hideyuki Kawashima, Patrick W. Serruys, Hironori Hara, Masafumi Ono, Chao Gao, Rutao Wang, Scot Garg, Faisal Sharif, Robbert J. de Winter, Michael J. Mack, David R. Holmes, Marie‐Claude Morice, A. Pieter Kappetein, Daniel J.F.M. Thuijs, Milan Milojevic, Thilo Noack, Friedrich‐Wilhelm Mohr, Piroze Davierwala, Yoshinobu Onuma
Jamie Diamond, Mahesh V. Madhavan, Joseph F. Sabik, Patrick W. Serruys, A. Pieter Kappetein, Martin B. Leon, David P. Taggart, Jacques Berland, Marie‐Claude Morice, Bernard J. Gersh, David E. Kandzari, Ovidiu Dressler, Gregg W. Stone
Hideyuki Kawashima, Masafumi Ono, Hironori Hara, Robbert J. de Winter, David R. Holmes, Daniel J.F.M. Thuijs, Milan Milojevic, Scot Garg, Patrick W. Serruys, Yoshinobu Onuma
Discussion(0)
No comments yet. Be the first to comment.